乳腺癌组织TIL、miR-31-5p、UBE3A表达与生物学行为及新辅助化疗反应性间的关系-现代医学

乳腺癌组织TIL、miR-31-5p、UBE3A表达与生物学行为及新辅助化疗反应性间的关系

单位：内江市第一人民医院甲状腺乳腺外科, 四川内江 641000

分类号：R737.9

出版年·卷·期（页码）：2022·50·第十二期（1500-1507）

摘要：

目的：探讨乳腺癌(BC)组织中肿瘤浸润淋巴细胞(TIL)、微小RNA-31-5p (miR-31-5p)、泛素蛋白连接酶E3A (UBE3A)的表达及其与生物学行为及新辅助化疗反应性间的关系。方法：选取2018年1月至2021年6月来我院就诊的BC患者93例为观察组，均进行新辅助化疗治疗，同期选取乳腺良性肿瘤患者61例为对照组。对比两组不同生物学行为病灶组织TIL、miR-31-5p、UBE3A的表达，分析TIL、miR-31-5p、UBE3A表达与新辅助化疗反应性间的关系。结果：观察组TIL、UBE3A表达高于对照组，miR-31-5p表达低于对照组，差异具有统计学意义(P＜0.05)；TIL、miR-31-5p、UBE3A表达与淋巴结转移、组织学分级、临床分期、分化程度、组织学类型有关(P＜0.05)；TIL、UBE3A高表达及miR-31-5p低表达均会增加化疗耐药风险(P＜0.05)；TIL、miR-31-5p、UBE3A联合预测效能高于单一指标预测(P＜0.05)。结论：BC患者TIL、miR-31-5p、UBE3A表达与生物学行为有关，联合检测在治疗反应性预测中具有较高效能。

Objective: To explore the relationship between the expressions of breast cancer(BC) tumor infiltrating lymphocytes(TIL), miR-31-5p, ubiquitin protein ligase E3A(UBE3A) and biological behavior and neoadjuvant chemotherapy responsiveness. Methods: 93 BC patients attending our hospital from January 2018 to June 2021 were selected as the observation group, and they were all treated with neoadjuvant chemotherapy. 61 patients with benign breast tumors were selected as the control group during the same period. The expressions of TIL, miR-31-5p, UBE3A in focal tissues were compared between the two groups with different biological behaviors. The relationship between TIL, miR-31-5p, UBE3A expressions and neoadjuvant chemotherapy responsiveness were analyzed. Results: The expressions of TIL and UBE3A in the observation group were higher than that of the control group, and the expressions of miR-31-5p was lower than that of the control group(P＜0.05).The expressions of TIL, miR-31-5p and UBE3A were related to lymph node metastasis, histological grade, clinical stage, degree of differentiation, and histological type(P<0.05). High expressions of TIL, UBE3A and low expressions of miR-31-5p would increase the risk of chemotherapy resistance(P＜0.05).The combined predictive power of TIL, miR-31-5p and UBE3A was higher than that of a single index(P＜0.05). Conclusion: The expressions of TIL, miR-31-5p and UBE3A in BC patients were related to biological behaviors, and combined detection had a high efficiency in predicting treatment response.

参考文献：

[1] QASEEM A,LIN J S,MUSTAFA R A,et al.Screening for breast cancer in average-risk women: a guidance statement from the American college of physicians[J].Ann Intern Med,2019,170(8):547-560.
[2] 邵英,杨永芳,秦明芳,等.云南省成年妇女乳腺癌与宫颈癌筛查率及影响因素分析[J].中国肿瘤,2019,28(11):821-826.表6 TIL、miR-31-5p、UBE3A表达预测新辅助化疗反应性的价值 Tab 6 Value of analyzing TIL, miR-31-5p, and UBE3A expression to predict responsiveness to neoadjuvant chemotherapy 参数曲线下面积(AUC)值95%CIZ值P值截断值灵敏性/%特异性/%TIL0.7850.687～0.8635.810＜0.001＞25.68%85.1962.12miR-31-5p0.8580.771～0.9228.713＜0.001≤3.0470.3786.66UBE3A0.8520.764～0.9177.898＜0.001＞0.6966.6780.91三者联合0.9490.883～0.98420.434＜0.00188.8990.91
[3] 侯晓峰,于晶晶,侯晓辉,等.PAM50基因突变与即刻乳房重建术治疗乳腺癌疗效的关系及对术后生存的预测[J].现代医学,2021,49(7):724-728.
[4] LAW A M,LIM E,ORMANDY C J,et al.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy[J].Endocr Relat Cancer,2017,24(4):R123-R144.
[5] LIU J,WANG T,XIAO B,et al.Fluorometric determination of the breast cancer 1 gene based on the target-induced conformational change of a DNA template for copper nanoclusters[J].Anal Methods,2021,13(5):712-718.
[6] 荣欣欣,黄红梅,李静佳,等.乳腺癌中泛素蛋白连接酶E3A与泛素特异性蛋白酶25的表达及其临床意义[J].实用医学杂志,2020,36(1):27-32.
[7] BADALAMENTI G,FANALE D,INCORVAIA L,et al.Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone[J].Cell Immunol,2019,343(1):103753.
[8] 谢少利,刘家有,王碧娟,等.泛素蛋白连接酶E3A在乳腺癌细胞中作用的蛋白质组学与生物信息学分析[J].中国普通外科杂志,2019,28(5):590-596.
[9] HASHEMI Z S,MOGHADAM M F,FAROKHIMANESH S,et al.Inhibition of breast cancer metastasis by co-transfection of miR-31/193b-mimics[J].Iran J Basic Med Sci,2018,21(4):427-433.
[10] 中国乳腺癌新辅助治疗专家组.中国乳腺癌新辅助治疗专家共识(2019年版)[J].中国癌症杂志,2019,29(5):390-400.
[11] 杨文涛,步宏.乳腺癌新辅助化疗后的病理诊断专家共识[J].中华病理学杂志,2015,44(4):232-236.
[12] MARX A,STRÖBEL P,BADVE S S,et al.ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions,histological criteria and reporting[J].J Thorac Oncol,2014,9(5):596-611.
[13] 曾愈程,康颖,刘芳,等.乳腺癌新辅助化疗疗效与预后关系研究进展[J].实用医学杂志,2018,34(10):1610-1612,1617.
[14] HORTON B L,WILLIAMS J B,CABANOV A,et al.Intratumoral CD8⁺ T-cell apoptosis is a major component of T-cell dysfunction and impedes antitumor immunity[J].Cancer Immunol Res,2018,6(1):14-24.
[15] LINETTE G P,CARRENO B M.Tumor-infiltrating lymphocytes in the checkpoint inhibitor era[J].Curr Hematol Malig Rep,2019,14(4):286-291.
[16] PRUNERI G,VINGIANI A,DENKERT C.Tumor infiltrating lymphocytes in early breast cancer[J].Breast,2018,37:207-214.
[17] ESBAH O,OKSUZOGLU B.Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer[J].Indian J Med Res,2017,146(5):563-571.
[18] 蒋伟刚,刘耀升,刘蜀彬,等.乳腺癌脊柱转移瘤术后转归及预后因素分析[J].脊柱外科杂志,2017,15(2):111-116.
[19] 安杰,曾令瑞,宋婷婷,等.肿瘤间质比和肿瘤浸润淋巴细胞对淋巴结转移乳腺癌预后的影响[J].临床与实验病理学杂志,2020,36(3):285-290.
[20] TOSS M S,MILIGY I,AL-KAWAZ A,et al.Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast[J].Mod Pathol, 2018,31(8):1226-1236.
[21] 昝大立,杜向斌,王楷群,等.肿瘤细胞间黏附性对免疫逃逸的影响[J].医用生物力学,2019,34(2):145-152.
[22] 张雨生,陈尧光,李思宁,等.免疫抑制性受体TIGIT在癌症免疫周期中的作用[J].中国综合临床,2018,34(1):89-91.
[23] 韩一栩,周小飞,陈春妃,等.土木香提取物通过下调miR-31-5p表达调控宫颈癌细胞增殖和凋亡的机制研究[J].中国免疫学杂志,2020,36(4):433-438.
[24] SHEN X,LEI J,DU L.miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC[J].Exp Ther Med,2020,19(1):375-383.
[25] 严孝岭,刘国瑞,李晓军,等.血清七种自身抗体与传统肿瘤标志物在肺癌诊断中的价值分析[J].东南大学学报(医学版),2022,41(4):505-510.
[26] KOHLI S,BHARDWAJ A,KUMARI R,et al.SIRT6 is a target of regulation by UBE3A that contributes to liver tumorigenesis in an ANXA2-dependent manner[J].Cancer Res,2018,78(3):645-658.
[27] HOESLI R,BIRKELAND A C,ROSKO A J,et al.Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma[J].Oral Oncol,2018,77(1):83-89.
[28] 金珊珊,束永前.中晚期非小细胞肺癌患者培美曲塞联合铂类化疗前后免疫抑制细胞检测及意义[J].中华肿瘤防治杂志,2018,25(22):1583-1587.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录